Sten Verland, PhD
Sten Verland is one of the three co-founders of Sunstone Life Science Ventures and focuses in particular on investment opportunities related to immuno-oncology, autoimmune diseases, and orphan diseases.
During his career, Sten has been active as a serial entrepreneur and business angel and has co-founded 10 start-ups, primarily in the biotech and CRO fields. While at Sunstone, Sten has played a key role in executing three M&A exits (Rigontec, Action Pharma and Zymenex) and one IPO (Orphazyme).
Sten holds a master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen. Sten serves as a board member of the Danish Venture Capital and Private Equity Association (DVCA).
Phone: +45 2422 1969